



08-09-07

Express Mail No. EB 132 602 322 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Storer, *et al.*

Confirmation No.: 2201

Serial No.: 10/608,907

Art Unit: 1623

Filed: June 27, 2003

Examiner: Travis C. McIntosh III

For: MODIFIED 2' AND 3'  
NUCLEOSIDE PRODRUGS FOR  
TREATING FLAVIVIRIDAE  
INFECTIONS

Attorney Docket No.: 11874-055-999  
(417451-999055)  
IDX 1018

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. § 1.56

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 and § 1.97 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby direct the Examiner's attention to the references listed on the attached List of References Cited by Applicant.

Copies of References B01 to B11 and C01 to C06 are submitted herewith. References A01 to A18 are U.S. patents and U.S. published applications. Therefore, copies of these references are not submitted herewith, pursuant to 37 C.F.R. § 1.98(a)(2)(ii).

Applicants respectfully request that the Examiner review the listed references and that the references be made of record in the file history of the application. Identification of references listed on PTO Form 1449 is not to be construed as an admission of Applicants or attorneys for Applicants that such references are available as "prior art" against the subject application.


Respectfully submitted,

Date: August 7, 2007

Dale L. Rieger

Reg. No. 43,045

JONES DAY  
222 East 41st Street  
New York, New York 10017  
(858) 314-1200



**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

<b>ATTY. DOCKET NO.</b> 11874-055-999	<b>APPLICATION NO.</b> 10/608,907
<b>APPLICANT</b> Storer, et al.	<b>CONFIRMATION NO.</b> 2201
<b>FILING DATE</b> June 27, 2003	<b>ART UNIT</b> 1623

**U.S. PATENT DOCUMENTS**

*Examiner Initials		Document Number	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A01	4,880,784	11/14/89	Robins, et al.	
	A02	5,156,797	10/26/93	Chou, et al.	
	A03	5,371,210	12/06/94	Chou, et al.	
	A04	5,401,861	3/28/95	Chou, et al.	
	A05	5,606,048	2/25/97	Chou, et al.	
	A06	5,821,357	10/13/98	Chou, et al.	
	A07	6,815,542	11/9/04	Hong, et al.	
	A08	6,914,054	7/05/05	Sommadossi, et al.	
	A09	7,101,861	9/05/06	Sommadossi, et al.	
	A10	7,105,493	9/12/06	Sommadossi, et al.	
	A11	7,148,206	12/12/06	Sommadossi, et al.	
	A12	7,157,441	1/02/07	Sommadossi, et al.	
	A13	7,163,929	1/16/07	Sommadossi, et al.	
	A14	2003/0055013	3/20/03	Brass	
	A15	2004/0077587	4/22/04	Sommadossi, et al.	
	A16	2004/0097461	5/20/04	Sommadossi, et al.	
	A17	2004/0101535	5/27/04	Sommadossi, et al.	
	A18	2005/0124532	6/09/05	Sommadossi, et al.	

**FOREIGN PATENT DOCUMENTS**

*Examiner Initials		Foreign Patent Document Country Code, Number, Kind Code (if known)	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
	B01	GB 1187824	5/02/66	Merck & Co., Inc.		
	B02	JP 06211890	8/02/94	Yamasa Shoyu Co. Ltd.	English abstract provided.	
	B03	WO 99/052514	10/21/99	Eli Lilly and Co.		
	B04	WO 04/065398	8/5/04	Ribapharm, Inc.		
	B05	WO 04/080466	9/23/04	Ribapharm, Inc.		
	B06	WO 05/012327	2/10/05	University College Cardiff Consultants Limited		

LAI-2888331v1

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

<b>ATTY. DOCKET NO.</b> 11874-055-999	<b>APPLICATION NO.</b> 10/608,907
<b>APPLICANT</b> Storer, et al.	<b>CONFIRMATION NO.</b> 2201
<b>FILING DATE</b> June 27, 2003	<b>ART UNIT</b> 1623

**FOREIGN PATENT DOCUMENTS**

*Examiner Initials		Foreign Patent Document Country Code, Number, Kind Code (if known)	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
	B07	WO 05/021568	3/10/05	Biota, Inc.		
	B08	WO 05/030258	4/07/05	Dihedron Corp.		
	B09	WO 05/123087	12/29/05	Merck & Co., Inc.		
	B10	WO 06/002231	1/05/06	Biocryst Pharmaceuticals, Inc.		
	B11	WO 06/012078	2/02/06	Merck & Co., Inc.		

**NON PATENT LITERATURE DOCUMENTS**

*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C01	Berenguer, M., et al., "Hepatitis B and C viruses: Molecular identification and targeted antiviral therapies," Proceedings of the Association of American Physicians, 110(2), 98-112 (1998).	
	C02	Kotra, L., et al., "Structure-Activity Relationships of 2'-Deoxy-2',2'-difluoro-L-erythro-pentofuranosyl Nucleosides." J. Med. Chem. 1997, 40, 3635-3644.	
	C03	Kuhn, R., et al., "Über eine molekulare Umlagerung von N-Glucosiden." Jahrg. 69, 1936, p. 1745-1754.	
	C04	Savochkina, et al., "Substrate Properties of C-MethylNucleoside Triphosphates in RNA Syntheses Catalyzed by E. Coli RNA - Polymerase." Molecular Biology, 1989, v. 23, no. 6.	
	C05	Zinchenko, et al., "2', 3' & .5' - uridine methyl derivatives in microbiological translocation." Doklady Akad. Nauk v.297(3), pp. 731-734.	
	C06	Zinchenko, et al., "Substrate specificity of uridine and purine nucleoside phosphorases in whole cells of e. coli" Biopolymers & a cell, 1988, v. 4, No. 6.	

LAI-2888331v1

**EXAMINER****DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.